The impact of hepatitis B vaccine in China and in the China GAVI Project
The impact of hepatitis B vaccine in China and in the China GAVI Project
复制标题
DOI：
10.1016/j.vaccine.2013.03.043
复制
发表时间：
2013-12-27
期刊：
影响因子：
5.5
通讯作者：
Yang Weizhong
中科院分区：
文献类型：
--
作者：
Hadler, Stephen C.;Cui Fuqiang;Yang Weizhong
中国疫苗和免疫联盟项目（CGP）于2002年启动，旨在为中国西部省份和中部省份贫困县等欠发达地区出生的婴儿提供乙肝疫苗，以预防乙肝病毒感染的后果。到2009年，项目区已将3剂乙肝疫苗和及时出生疫苗的婴儿覆盖率提高到近90%，与较富裕的东部省份相当，并将乙肝病毒流行率降至
The China GAVI Project (CGP) was initiated in 2002 to provide hepatitis B (HB) vaccine to infants born in the less developed areas of China including the Western provinces and poverty counties of Middle provinces, to prevent the consequences of hepatitis B virus infection. By 2009, the project areas had raised coverage of 3 doses of HB vaccine and timely birth doses to almost 90% among infants, comparable to those in wealthier Eastern provinces, and reduced HBV prevalence to